News

Biotech behind Eli Lilly obesity pill aims for new standard of care
The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting drug it has developed to create a new standard of patient care for weight ...
The Zimbabwean on MSN3h
Digital Health Solutions For Non-Communicable Disease Care in Zimbabwe
Sharing data in real time to make critical health care decisionsConnecting rural and remote communities to Zimbabwe’s primary ...
Novo Nordisk Stock (NVO) Shakes off Links Between Weight Jabs and Vision Loss
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
MarketBeat on MSN15h
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...
Bank of America Securities Remains a Buy on Eli Lilly & Co (LLY)
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly is said to have posted 60% rise in obesity drug sales in India last month
Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.
81,000 Vials, Rs 24 Crore In 3 Months: Weight Loss Drug Mounjaro Sales Triple As Patients Shift To Higher Dose
With three months since its launch in India, according to latest Pharmatrac data, Mounjaro clocked Rs 12.6 crore in sales in May 2025—a threefold increase from March ...
Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...